Indian pharma deals landscape shaped by Covid-19
The number of deals made in the Indian pharma market increased by 22% from 2019 to 2020, likely due to the Covid-19 pandemic.
Markets
Why Covid-19 didn’t hurt tech brands’ appetite for Asian investment
Novartis aiming to expand patient reach for world’s most expensive drug, Zolgensma
Microbiome-targeting pipeline addresses multiple immunological indications
EHA 2021: primary endpoints met in final analysis of EURO-SKI trial in CML
Novavax’s Covid-19 vaccine may face severe uptake challenges in the US
Interim data from tenapanor’s OPTIMIZE trial signals promising option for CKD-HP
Covid-19 vaccine purchasing in EU likely to pivot to traditional reimbursement models from 2023
